<unk>  is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who have: * chronic IBS symptoms (generally lasting 6 months or longer), * had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and * not responded adequately to conventional therapy. Severe IBS-D includes: diarrhea and 1 or more of the following: * frequent and severe abdominal pain/discomfort, * frequent bowel urgency or fecal incontinence, * disability or restriction of daily activities due to IBS. Efficacy The phase III trial for approval was published in 2000 as an industry-funded randomised, placebo-controlled trial (PCT). Its authors found 1 mg<unk> , taken orally twice daily for 12 weeks, was associated with a 12% (CI 4.7-19.2) improvement in relief from abdominal pain and discomfort associated with diarrhoea-predominant patients. The prescription of<unk>  is currently approved in the U.S. at 0.5 and 1 mg. The FDA Medical Officer's Review, dated November 4, 1999, noted: “Patients considered by investigators to fit the diarrhea-predominant subtype had at baseline… stool consistency values that were neither loose nor watery”. The FDA's Gastrointestinal Drugs Advisory Committee referred to the drug's efficacy as "modest", highlighting that the placebo brought relief on the primary outcome measure to 40–50% of women.
Alosetron
Tropisetron
Granisetron
Cilansetron
Palonosetron
Avacopan
Agomelatine
Bocasan